AblaCare Company
.jpg)
AblaCare has developped an innovative solution for Polycystic Ovary Syndrome (PCOS) related infertility, designed to provide women with more natural and less medicalized pregnancy. PCOS is the #1 cause of female infertility. Since 2017, they have been working on developing an innovative solution, aiming to restore ovulation in patients through a simple, one-time, durable, minimally invasive treatment. The Procedure can be performed in a clinic setting, without General Anesthesia, using the same minimally invasive access commonly used by fertility physicians for IVF.
Total Funding:
$11,204,444
Headquarters:
Paris, Ile-de-France, France
Funding Status:
Early Stage Venture
Employee Number:
1-10
Estimated Revenue:
$1M to $10M
Last Funding Type:
Series A
Last Funding Date:
2019-07-09
Investors Number:
2
Founded Date:
01-01-2017
Industry:
Reproductive Health & Contraception